Last reviewed · How we verify
Placebo Tab
Placebo produces no pharmacological effect, serving as an inert control to measure the psychological and contextual benefits of treatment.
Placebo produces no pharmacological effect, serving as an inert control to measure the psychological and contextual benefits of treatment. Used for Control arm in phase 3 clinical trials (non-therapeutic use).
At a glance
| Generic name | Placebo Tab |
|---|---|
| Also known as | placebo tablet |
| Sponsor | Region Örebro County |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo tablets contain no active pharmaceutical ingredient and work through the placebo effect—a phenomenon where patients experience symptom improvement due to expectation, belief, and the clinical context rather than direct drug action. This is commonly used in clinical trials as a control arm to isolate the true efficacy of an investigational drug from psychological and environmental factors.
Approved indications
- Control arm in phase 3 clinical trials (non-therapeutic use)
Common side effects
- Placebo effect (symptom improvement without active ingredient)
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Adenosine 2A Receptor Antagonism and AIH in ALS (PHASE1, PHASE2)
- Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria (PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Tab CI brief — competitive landscape report
- Placebo Tab updates RSS · CI watch RSS
- Region Örebro County portfolio CI